Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity.

Blood - 15 Dec 2003

Tellam Judy, Connolly Geoff, Webb Natasha, Duraiswamy Jaikumar, Khanna Rajiv

Abstract excerpt

The ability of viral or mutated cellular oncogenes to initiate neoplastic events and their poor immunogenicity have considerably undermined their potential use as immunotherapeutic tools for the treatment of human cancers. Using an Epstein-Barr virus-encoded oncogene, latent membrane protein 1 (L...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3 Cells
Share to Cell Transformation, Viral
Share to Cysteine Endopeptidases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to H-2 Antigens

Share to Herpesvirus 4, Human

Share to Multienzyme Complexes

Share to Neoplasms, Experimental

Share to Viral Matrix Proteins

Source

Identifiers

PMID: 12920032
DOI: 10.1182/blood-2003-03-0870

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12920032-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity.PMID 12920032Read ↗

A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways.Semantic proximity Read ↗

Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregationSemantic proximity Read ↗

Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue.Semantic proximity Read ↗

EPSTEIN-BARR VIRUS LMP1 ENHANCES LEVELS OF MICROVESICLE-ASSOCIATED PD-L1Semantic proximity Read ↗

Functionally significant mutations in the Epstein-Barr virus LMP1 gene and their role in activation of cell signaling pathways.Semantic proximity Read ↗

Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinomaSemantic proximity Read ↗

The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain.Semantic proximity Read ↗

Immunotherapeutic strategies for EBV-associated malignancies.Semantic proximity Read ↗

Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.Semantic proximity Read ↗

The Potent Oncogene NPM-ALK Mediates Malignant Transformation of Normal Human CD4+ T LymphocytesSemantic proximity Read ↗

Mutational analysis of the transforming function of the EBV encoded LMP-1.Semantic proximity Read ↗

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.